Published in PLoS One on May 21, 2008
Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity. J Neurosci (2009) 1.52
Retracted Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Mol Cancer (2013) 1.41
Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid (2010) 1.28
Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei. Mol Cell Proteomics (2010) 1.19
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer (2010) 1.14
17β-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS One (2011) 1.12
Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One (2008) 1.08
Androgen-induced cell migration: role of androgen receptor/filamin A association. PLoS One (2011) 1.06
Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer (2011) 1.06
Brain sex differences and hormone influences: a moving experience? J Neuroendocrinol (2009) 0.96
Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology (2010) 0.96
Alcohol promotes breast cancer cell invasion by regulating the Nm23-ITGA5 pathway. J Exp Clin Cancer Res (2011) 0.93
Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics (2010) 0.86
Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis (2015) 0.86
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? Breast Cancer Res (2012) 0.83
Luminal breast cancer metastasis is dependent on estrogen signaling. Clin Exp Metastasis (2012) 0.82
Extranuclear signaling by estrogen: role in breast cancer progression and metastasis. Minerva Ginecol (2010) 0.81
Ovarian steroids increase spinogenetic proteins in the macaque dorsal raphe. Neuroscience (2012) 0.81
Estradiol increases ER-negative breast cancer metastasis in an experimental model. Clin Exp Metastasis (2013) 0.80
Rapid effects of oestrogen on synaptic plasticity: interactions with actin and its signalling proteins. J Neuroendocrinol (2013) 0.80
CDK11p58 inhibits ERα-positive breast cancer invasion by targeting integrin β3 via the repression of ERα signaling. BMC Cancer (2014) 0.79
Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med (2014) 0.78
Steroid signaling activation and intracellular localization of sex steroid receptors. J Cell Commun Signal (2010) 0.77
Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis (2015) 0.77
Sex Hormones Regulate Cytoskeletal Proteins Involved in Brain Plasticity. Front Psychiatry (2015) 0.76
Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells. Oncotarget (2017) 0.75
Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells. Horm Cancer (2014) 0.75
Formononetin promotes angiogenesis through the estrogen receptor alpha-enhanced ROCK pathway. Sci Rep (2015) 0.75
17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. Carcinogenesis (2015) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Cellular motility driven by assembly and disassembly of actin filaments. Cell (2003) 26.05
Reproductive factors and breast cancer. Epidemiol Rev (1993) 8.37
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Periodic lamellipodial contractions correlate with rearward actin waves. Cell (2004) 6.46
Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol (1998) 5.15
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med (2004) 4.28
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med (2004) 2.90
Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem (1999) 2.60
Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol (2004) 2.34
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci (1997) 2.11
Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem (1998) 2.09
The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res (2005) 1.76
Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev (2001) 1.74
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology (2000) 1.50
Non-genomic actions of sex steroid hormones. Eur J Endocrinol (2003) 1.48
Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem (2006) 1.35
Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol (2006) 1.35
Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology (2005) 1.15
Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat (2006) 1.12
Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer (2001) 1.07
Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett (2005) 1.01
RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate. J Biol Chem (2002) 0.98
Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype. Surgery (1998) 0.86
Role for moesin in lipopolysaccharide-stimulated signal transduction. Infect Immun (2004) 0.81
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol (2005) 3.19
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 3.17
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol (2009) 1.90
Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A (2006) 1.79
Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer (2003) 1.69
Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer. J Clin Oncol (2009) 1.64
Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat (2004) 1.62
The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol (2007) 1.61
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology (2011) 1.61
Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. Am J Surg (2007) 1.48
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril (2002) 1.45
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res (2006) 1.44
Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. Ann Surg Oncol (2012) 1.44
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest (2010) 1.41
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol (2007) 1.40
Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest (2002) 1.40
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol (2006) 1.35
Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother (2004) 1.30
miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J (2012) 1.27
AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J (2008) 1.24
Genomic and non-genomic effects of estrogens on endothelial cells. Steroids (2004) 1.20
Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol (2010) 1.12
Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol (2005) 1.12
Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol (2012) 1.10
Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One (2008) 1.08
In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol (2008) 1.07
MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res (2011) 1.07
Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol (2004) 1.06
Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med (2010) 1.05
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer (2010) 1.04
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene (2005) 1.03
New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas (2005) 1.03
Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. Cancer (2007) 1.02
Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res (2009) 1.01
Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol (2007) 1.01
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol (2008) 1.01
Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer (2007) 1.01
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas (2008) 1.00
Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecol Endocrinol (2012) 1.00
Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol (2006) 1.00
Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol (2006) 0.99
Extra-nuclear signaling of estrogen receptors. IUBMB Life (2008) 0.98
Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem (2006) 0.98
Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol (2012) 0.98
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res (2013) 0.98
Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology (2010) 0.98
Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol (2005) 0.98
Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids (2002) 0.98
Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology (2003) 0.97
Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg (2013) 0.97
Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. Endocr Relat Cancer (2010) 0.97
Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology (2004) 0.96
Rapid regulatory actions of sex steroids on cell movement through the actin cytoskeleton. Steroids (2008) 0.96
Compensatory feto-placental upregulation of the nitric oxide system during fetal growth restriction. PLoS One (2012) 0.95
Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab (2008) 0.95
Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol (2009) 0.95
Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin Chem (2002) 0.94
Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol (2008) 0.94
Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells. Horm Cancer (2012) 0.93
Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol (2006) 0.93
Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol (2010) 0.93
Menopause after breast cancer: a survey on breast cancer survivors. Maturitas (2003) 0.92
The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol (2004) 0.92
Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecol Endocrinol (2008) 0.90
Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region. Biochem J (2004) 0.90
An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival. Carcinogenesis (2013) 0.90
Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod (2008) 0.90
Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol (2005) 0.90